Developing Therapeutic Treatments for Chronic Neuropathic Pain and Sensorineural Hearing Loss
Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss - indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.
Our science is based on the discovery of a novel family of endogenous human proteins: meteorin and cometin. These neurotrophic factors are involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.
Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.